ABBOTT LABORATORIES acquired Facet Biotech Corporation for $27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net), a transaction completed in April 2010, structured as all cash (tender offer and merger).
Facet Biotech Corporation operates in Biopharmaceuticals — early-stage R&D, is based in Redwood City, California, USA. Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform.
Expands Abbott's early- and mid-stage biologics pipeline and antibody-research capabilities.
Added a biologics pipeline and antibody-engineering technology to Abbott's pharmaceutical research. Integrated into Abbott's pharmaceutical R&D
Advisory firms were not disclosed for this transaction.